CD274 and gastroesophageal junction adenocarcinoma: In Asian populations, the phase III ORIENT-16 trial demonstrated that sintilimab plus chemotherapy significantly prolonged OS compared with chemotherapy alone—in the overall population (15.2 vs. 12.3 months; HR = 0.77, P = 0.009) and particularly in patients with PD-L1 CPS ≥5 (19.2 vs. 12.9 months; HR = 0.66, P < 0.001)—supporting its use as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma in Chinese patients (19).Similarly, in the Chinese subgroup of CheckMate-649, 5-year OS reached 24% versus 8% with chemotherapy alone in CPS≥5 patients (20, 21).